1-8 of 8
Olivier Catalani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 4732.
https://doi.org/10.1182/blood-2024-199519
Published: 2024
Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg
Journal: Blood
Blood (2021) 138 (Supplement 1): 343.
https://doi.org/10.1182/blood-2021-146009
Published: 2021
Journal Articles

Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

William Townsend, MRCP,MDFRCPath, Christian Buske, MD, Guillaume Cartron, David Cunningham, Martin JS Dyer, John G. Gribben, Georg Hess, Takayuki Ishikawa, Ulrich Keller, Michael Kneba, Ram Malladi, Jeffrey D Neidhart, Chiara Rusconi, Jun Zhu, Olivier Catalani, Andrea Knapp, Harald Zeuner, Michael Herold, Wolfgang Hiddemann, Robert Marcus
Journal: Blood
Blood (2018) 132 (Supplement 1): 1597.
https://doi.org/10.1182/blood-2018-99-115167
Published: 2018
Journal Articles

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse-Jarres, Christine L Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, MDPhD, Guy Young, Johannes Oldenburg
Journal: Blood
Blood (2017) 130 (Supplement 1): 1071.
https://doi.org/10.1182/blood.V130.Suppl_1.1071.1071
Published: 2017
Journal Articles

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Michael U. Callaghan, Claude Negrier, Guy Young, Liane Khoo, Johnny Mahlangu, Jerzy Windyga, Johannes Oldenburg, Jin Xu, Olivier Catalani, Elina Asikanius, Joanne I. Adamkewicz, Midori Shima, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3668.
https://doi.org/10.1182/blood.V130.Suppl_1.3668.3668
Published: 2017
Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Umberto Vitolo, Marek Trněný, David Belada, Angelo M Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian W. Flinn, MD PhD, Xiaonan Hong, Won Seog Kim, Antonio Pinto, John M Burke, MD, Yuankai Shi, MD, Yoichi Tatsumi, Mikkel Oestergaard, Michael K Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, Laurie H Sehn, MD
Journal: Blood
Blood (2016) 128 (22): 470.
https://doi.org/10.1182/blood.V128.22.470.470
Published: 2016
Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS
Journal: Blood
Blood (2014) 124 (21): 1995.
https://doi.org/10.1182/blood.V124.21.1995.1995
Published: 2014
Journal Articles

Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)

Antonio Salar, MD, Irit Avivi, MD, Jean-Francois Larouche, MD, Andrea Janikova, MD, PhD, Juliana Pereira, PhD, Mike Brewster, Olivier Catalani, Christine McIntyre, Pakeeza Sayyed, Andrew Haynes
Journal: Blood
Blood (2012) 120 (21): 1641.
https://doi.org/10.1182/blood.V120.21.1641.1641
Published: 2012